Biomarkers in NAFLD
Research type
Research Study
Full title
Identification of new Biomarkers and Inflammatory Pathways in NAFLD and NASH.
IRAS ID
278924
Contact name
Emmanuel Tsochatzis
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
Duration of Study in the UK
5 years, 0 months, 4 days
Research summary
Non-alcoholic fatty liver disease is prevalent in 25% of the adult population in the UK and is the most common reason of secondary care referrals to secondary care Hepatology services. Despite its high prevalence, there is no licensed treatment as yet. Patient stratification is still reliant on liver biopsy, as non-invasive tests are not able to accurately diagnose a type of NAFLD, ‘non-alcoholic steatohepatitis (NASH)’ and to measure amount of liver fibrosis by staging, particularly at the early stages. We hope that with this piece of research we will be able to identify putative biomarkers for improved disease stratification and treatment selection.
REC name
London - Bromley Research Ethics Committee
REC reference
20/LO/1063
Date of REC Opinion
24 Sep 2020
REC opinion
Unfavourable Opinion